Optimal adjuvant chemotherapy in breast cancer: selection of agents

Espósito, Angela; Salè, Emanuela Omodeo; Curigliano, Giuseppe

doi:10.1586/17512433.2014.945429

Cited by 3 publications

(3 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of status for hormonal receptors was commonly reported. However, previous studies reported that the status of single hormonal receptor (ER or PR) was related to the outcome 19 . We found for the first time that ER(-)/PR (-) patients with MIBC had poorer prognosis compared with patients with MIBC who were either ER (+) or PR (+).…”

Section: Discussionmentioning

confidence: 95%

Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

Niu¹,

Wei²,

Yu³

et al. 2016

Cancer Biology &Amp; Medicine

View full text Add to dashboard Cite

Objective: Survival and treatment of patients with microinvasive breast cancer (MIBC) remain controversial. In this paper, we evaluated whether adjuvant chemotherapy is necessary for patients with MIBC to identify risk factors influencing its prognosis and decide the indication for adjuvant chemotherapy. Methods:In this retrospective study, 108 patients with MIBC were recruited according to seventh edition of the staging manual of the American Joint Committee on Cancer (AJCC). The subjects were divided into chemotherapy and non-chemotherapy groups.We compared the 5-year disease-free survival (DFS) and overall survival (OS) rates between groups. Furthermore, we analyzed the factors related to prognosis for patients with MIBC using univariate and multivariate analyses. We also evaluated the impact of adjuvant chemotherapy on the prognostic factors by subgroup analysis after median follow-up time of 33 months (13-104 months). Results:The 5-year DFS and OS rates for the chemotherapy group were 93.7% and 97.5%, whereas those for the nonchemotherapy group were 89.7% and 100%. Results indicate that 5-year DFS was superior, but OS was inferior, in the former group compared with the latter group. However, no statistical significance was observed in the 5-year DFS (P=0.

show abstract

Section: Discussionmentioning

confidence: 95%

Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

Niu¹,

Wei²,

Yu³

et al. 2016

Cancer Biology &Amp; Medicine

View full text Add to dashboard Cite

show abstract

“…Recommending treatment for patients with MIBC who had insufficient information caused by small sample size and varying definitions is quite difficult. Adjuvant chemotherapy plays a very important role in breast cancer treatment, especially for triple-negative breast cancer [44], [45]. However, risk-benefit balance of chemotherapy should be considered to avoid widespread use of aggressive treatments for patients with MIBC.…”

Section: Chemotherapymentioning

confidence: 99%

National Cancer Institute Experience in Micro-invasive Breast Carcinoma Treatment and Outcome

Salama¹,

Khater²,

Adel

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Background: Significant relationship between breast cancer immunophenotype and risk of recurrence either local and/or distant may help determine which patients might benefit more from axillary staging and whether axillary staging is warranted in all cases or not. Patients with microinvasive carcinoma can present with axillary LN. metastasis, with incidence ranges from 0% to 20% . Thus, sentinel node biopsies are considered for patients with microinvasive carcinoma. The role of axillary staging in MIBC is not well defined, with the rate of axillary L.N. metastases ranging 0–11 %. Current studies focus on the clinical characteristics of MIBC. However, only a few studies have evaluated the survival and treatment, especially adjuvant chemotherapy after surgery, for patients with MIBC.Methods: This is a retrospective study of 139 cases diagnosed with microinvasive breast carcinoma from 2011 to 2015 who were identified in the National Cancer Institute, Cairo University. The pathologic database of our hospital was searched to identify patients with a pathologic diagnosis of MIBC on surgical specimens. The clinical features, sonographic and mammographic images and pathology records were reviewed.Results: There is increased incidence of MIBC over the past decade. Patients with MIBC were managed surgically with BCS. MIBC have the good prognosis. However, patients who are negative hormonal receptors have relatively substantial risk of relapse within the first 5 years after surgical operation. Adjuvant chemotherapy can only improve the outcomes of patients with negative hormonal receptors. Further studies with prolonged follow-up of large cohort are warranted to assess the prognostic significance and treatment of this lesion.Keywords: MIBC, CIS, DCIS, BC

show abstract

“…Chemotherapy has been shown to have no benefit in luminal A BC patients, whereas the benefit of chemoendocrine therapies compared with endocrine therapy alone is significant for luminal B patients. 4 …”

mentioning

confidence: 99%

New Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index

Bigras

Dong²,

Canil³

et al. 2017

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

There is a pressing need for an objective decision tool to guide therapy for breast cancer patients that are estrogen receptor positive and HER2/neu negative. This subset of patients contains a mixture of luminal A and B tumors with good and bad outcomes, respectively. The 2 main current tools are on the basis of immunohistochemistry (IHC) or gene expression, both of which rely on the expression of distinct molecular groups that reflect hormone receptors, HER2/neu status, and most importantly, proliferation. Despite the success of a proprietary molecular test, definitive superiority of any method has not yet been demonstrated. Ki67 IHC scoring assessments have been shown to be poorly reproducible, whereas molecular testing is costly with a longer turnaround time. This work proposes an objective Ki67 index using image analysis that addresses the existing methodological issues of Ki67 quantitation using IHC on paraffin-embedded tissue. Intrinsic bias related to numerical assessment performed on IHC is discussed as well as the sampling issue related to the “peel effect” of tiny objects within a thin section. A new nonbiased stereological parameter (VV) based on the Cavalieri method is suggested for use on a double-stained Ki67/cytokeratin IHC slide. The assessment is performed with open-source ImageJ software with interobserver concordance between 3 pathologists being high at 93.5%. Furthermore, VV was found to be a superior method to predict an outcome in a small subset of breast cancer patients when compared with other image analysis methods being used to determine the Ki67 labeling index. Calibration methodology is also discussed to further this IHC approach.

show abstract

Optimal adjuvant chemotherapy in breast cancer: selection of agents

Cited by 3 publications

References 73 publications

Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

National Cancer Institute Experience in Micro-invasive Breast Carcinoma Treatment and Outcome

New Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index

Contact Info

Product

Resources

About